241 Stock Overview
An investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Alibaba Health Information Technology Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$5.15 |
| 52 Week High | HK$6.70 |
| 52 Week Low | HK$2.66 |
| Beta | 1.58 |
| 1 Month Change | 8.19% |
| 3 Month Change | 42.66% |
| 1 Year Change | 57.01% |
| 3 Year Change | 35.88% |
| 5 Year Change | -71.77% |
| Change since IPO | 302.34% |
Recent News & Updates
Is Alibaba Health Information Technology Limited (HKG:241) Potentially Undervalued?
Apr 22
Alibaba Health Information Technology Limited's (HKG:241) P/E Is Still On The Mark Following 32% Share Price Bounce
Feb 10Recent updates
Is Alibaba Health Information Technology Limited (HKG:241) Potentially Undervalued?
Apr 22Alibaba Health Information Technology Limited's (HKG:241) P/E Is Still On The Mark Following 32% Share Price Bounce
Feb 10Here's Why Alibaba Health Information Technology (HKG:241) Has Caught The Eye Of Investors
Feb 02Alibaba Health Information Technology's (HKG:241) Solid Earnings Have Been Accounted For Conservatively
Dec 19Earnings Tell The Story For Alibaba Health Information Technology Limited (HKG:241) As Its Stock Soars 30%
Oct 18What Does Alibaba Health Information Technology Limited's (HKG:241) Share Price Indicate?
Sep 23Alibaba Health Information Technology (HKG:241) Is Looking To Continue Growing Its Returns On Capital
Jul 03After Leaping 26% Alibaba Health Information Technology Limited (HKG:241) Shares Are Not Flying Under The Radar
Jun 07Alibaba Health Information Technology's (HKG:241) Solid Earnings Are Supported By Other Strong Factors
Jun 06Shareholder Returns
| 241 | HK Consumer Retailing | HK Market | |
|---|---|---|---|
| 7D | 10.8% | 7.3% | 1.5% |
| 1Y | 57.0% | 6.2% | 14.7% |
Return vs Industry: 241 exceeded the Hong Kong Consumer Retailing industry which returned 6.2% over the past year.
Return vs Market: 241 exceeded the Hong Kong Market which returned 14.7% over the past year.
Price Volatility
| 241 volatility | |
|---|---|
| 241 Average Weekly Movement | 12.7% |
| Consumer Retailing Industry Average Movement | 8.8% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in HK Market | 15.3% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 241's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 241's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 1,422 | Difan Shen | www.alihealth.cn |
Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. The company offers a range of prescription and over-the-counter drugs, nutritional supplements, medical devices, contact lenses, health food, adult and family planning products, healthcare and skincare products, and various other health-related products. It also provides medical and healthcare services, including medical checkups, nucleic acid testing, medical consultation, appointment-booking, vaccination, dental care, mental care, optometry, and nursing services, as well as traditional Chinese medicines.
Alibaba Health Information Technology Limited Fundamentals Summary
| 241 fundamental statistics | |
|---|---|
| Market cap | HK$82.83b |
| Earnings (TTM) | HK$1.29b |
| Revenue (TTM) | HK$30.21b |
64.4x
P/E Ratio2.7x
P/S RatioIs 241 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 241 income statement (TTM) | |
|---|---|
| Revenue | CN¥28.34b |
| Cost of Revenue | CN¥21.78b |
| Gross Profit | CN¥6.56b |
| Other Expenses | CN¥5.35b |
| Earnings | CN¥1.21b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.075 |
| Gross Margin | 23.15% |
| Net Profit Margin | 4.26% |
| Debt/Equity Ratio | 0% |
How did 241 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/03 19:08 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alibaba Health Information Technology Limited is covered by 29 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xiaomeng Zhuang | BofA Global Research |
| Shun Kei Law | CCB International Securities Limited |
| Hazim Bahari | CFRA Equity Research |